Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

67 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Klinische Dokumentation Med. V - Follow Up CLL/HCL - Klinische Dokumentation Med. V CLL/HCL

- 31/01/2022 - 1 Formulaire, 9 Groupes Item, 68 Eléments de données, 2 Langues
Groupes Item: Patienten-Stammdaten, Diagnose: CLL/ HCL, Charakteristika bei Erstdiagnose, Zytogenetik und Mutationsstatus, Nebendiagnosen, Biobank, Aktuelle Diagnostik, Aktueller Patientenstatus, Therapieverlauf
Dokumentation des Follow-Up für Patienten mit CLL/HCL am Universitätsklinikum Heidelberg. Prof. Dr. med. Sascha Dietrich; Dr. med. Tim Sauer; Medizinischen Klinik V - Klinik für Hämatologie, Onkologie, Rheumatologie - Universitätsklinikum Heidelberg

CLL Cycle 2 FCR vs FC BO17072 NCT00090051 - Chemotherapy Cycle 2 of Chronic Lymphocytic Leukemia NCT00090051 BO17072

- 27/09/2021 - 1 Formulaire, 11 Groupes Item, 59 Eléments de données, 1 Langue
Groupes Item: Vital signs and physical measurements, Sitting measurements, "B" symptoms, General physical examination, Administration of Rituximab, Day 1, Day 2, Administration of Fludarabine, Fludarabine Medication, Administration of Cyclophosphamide, Cyclophosphamide Medication
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients NCT00090051 Roche BO17072

Eligibility Leukemia, Lymphocytic, Chronic NCT00038415

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach; ODM derived from: https://clinicaltrials.gov/show/NCT00038415

Eligibility Chronic Lymphocytic Leukemia NCT00286780

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00286780

Eligibility Lymphocytic Leukemia, Chronic NCT01414205

- 12/07/2020 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE); ODM derived from: https://clinicaltrials.gov/show/NCT01414205

Eligibility Lymphocytic Leukemia, Chronic NCT01271010

- 12/07/2020 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status; ODM derived from: https://clinicaltrials.gov/show/NCT01271010

Eligibility Lymphocytic Leukemia, Chronic NCT01263704

- 12/07/2020 - 1 Formulaire, 2 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01263704

Eligibility Lymphocytic Leukemia, Chronic NCT01056510

- 11/07/2020 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe); ODM derived from: https://clinicaltrials.gov/show/NCT01056510

Eligibility Leukaemia, Lymphocytic, Chronic NCT01110031

- 16/06/2020 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT01110031

Eligibility Leukaemia, Lymphocytic, Chronic NCT01313689

- 15/06/2020 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01313689

Eligibility Chronic Lymphocytic Leukemia NCT02491398

- 28/02/2019 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02491398

Eligibility Chronic Lymphocytic Leukemia NCT02296918

- 28/02/2019 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL; ODM derived from: https://clinicaltrials.gov/show/NCT02296918

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial